Navigation Links
Inverness Medical Innovations Announces Fourth Quarter 2007 Results
Date:2/20/2008

ificant positive or

negative impact on results yet do not occur on a consistent or

regular basis in its business. In determining whether a particular

item meets one of these criteria, management considers facts and

circumstances that it believes are relevant. Management believes

that excluding such charges and income from income or loss allows

investors and management to evaluate and compare the Company's

operating results from continuing operations from period to period

in a meaningful and consistent manner. Due to the frequency of

their occurrence in its business, the Company does not adjust net

income or loss for the costs associated with litigation, including

payments made or received through settlements. It should be noted

that "net income or loss on an adjusted cash basis" is not a

standard financial measurement under accounting principles generally

accepted in the United States of America ("GAAP") and should not be

considered as an alternative to net income or loss or cash flow from

operating activities, as a measure of liquidity or as an indicator

of operating performance or any measure of performance derived in

accordance with GAAP.

(b) Restructuring charge associated with the decision to close

facilities of $5.2 million and $1.2 million for the three months

ended December 31, 2007 and 2006, respectively. The $5.2 million

charge for the three months ended December 31, 2007 includes: $2.0

million charged to cost of sales, $2.2 million charged to research

and development, and $1.0 million charged to selling, general and

administrative expense. The $1.2 million charge for the three

months ended December 31, 2006 was charged to cost of sales. These'/>"/>

SOURCE Inverness Medical Innovations
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Inverness Medical Innovations Completes Acquisition of BBI Holdings Plc
2. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
3. Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
4. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 8, 2008
5. Inverness Medical Innovations Acquires ParadigmHealth
6. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
7. Inverness Medical Innovations Announces Proposed Public Offering of Common Stock
8. Inverness - Chemogen Establish Exclusive License for TB Antibodies
9. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
10. B-Line Medical and Immersion Medical Announce Partnership
11. MIT researcher addresses biomedical engineering challenges
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... 31, 2015 , ... R-Biopharm is proud to announce the ... in foods, has been accepted by AOAC International as Official First Action method. ... Cereal-Based Products by R5 Competitive ELISA,” based on a specific monoclonal antibody to ...
(Date:7/30/2015)... , ... July 30, 2015 , ... The 2015 Market ... study on the current state of the global Propanol market with a focus on ... BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG ...
(Date:7/30/2015)... DALLAS , July 30, 2015  With over 60,000 customers across the globe, ISN ... helps connect 450 hiring organizations with more than 60,000 safe and reliable contractors in over 80 ... ... ... Headquartered in Dallas, ...
(Date:7/30/2015)... ... July 30, 2015 , ... GEA's ... designed for continuous operation up to 1500 bar. The sanitary design gauge of ... preventing toxic contamination. , The Pony™ NS2006L homogenizer is an ideal solution for ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... to Continue as President and CSO, MONTREAL ... a privately held biotechnology company developing,first-in-class Leukocyte Population ... appointment of Jack M. Anthony to Chief,Executive Officer. ... of,CEO will continue as President and assume the ...
... will present at the William Blair & Company ... 10:40 a.m. ET at the New York Palace,Hotel, ... Officer and Dr.,David Persing, Cepheid,s Chief Medical and ... webcast, along with accompanying presentation slides, may be,accessed ...
... cancer ... drug development, MILAN, Italy, Sept. 26 ... shareholders meeting,(Annual Meeting) on Tuesday, September 25, 2007 in Milan. The Company,conducted ... by Italian shareholders. At the 2007 Annual Meeting, shareholders,re-elected Mary O. Mundinger, ...
Cached Biology Technology:Osprey Pharmaceuticals Names Jack M. Anthony as CEO 2Osprey Pharmaceuticals Names Jack M. Anthony as CEO 3Cepheid to Present at William Blair Small-Cap Growth Stock Conference 2Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results 2Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results 3Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results 4
(Date:7/31/2015)... OXFORD, Conn. , Jul. 31, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces that it has filed provisional patent 62/198989 for ... This invention highlights a method to advance crypto-currencies ... technology by introducing a common, uniform way to manage ...
(Date:7/30/2015)... MOUNTAIN VIEW, Calif. , July 30, 2015 ... products and services for gene function analysis and ... CRISPR Guide RNA (sgRNA) Knockout Library targeting all ... to specifically and permanently "knock out" a gene,s ... library provides a high throughput screening tool so ...
(Date:7/27/2015)... ANGELES , July 27, 2015   ... evidence- and experience-based clinical improvement solutions, today announced ... solution is now available on Android smartphones and ... inpatient and post-care organizations can use ZynxCarebook to ... same patient,s condition, streamline care transitions to other ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... European Congress on Osteoporosis & Osteoarthritis (ESCEO13-IOF) Rome, Italy ... European Accreditation Council for Continuing Medical Education (EACCME) credits. ... of AMA PRA Category 1 Credits. Visit ... Selected highlights from our broad, high-quality programme: ...
... A new study from the University of Maryland School of ... ability of brain cells to communicate with each other. The ... depression is caused and how it should be treated. Instead ... brain, such as serotonin, the scientists found that the transmission ...
... from the ice sheet, despite having some physical connection to ... The discovery, just published in Geophysical Research Letters , ... of the future contribution of Greenland,s ice to sea-level rise. ... from space, and a recently completed inventory of Greenland,s glaciers ...
Cached Biology News:University of Maryland School of Medicine finds depression stems from miscommunication between brain cells 2University of Maryland School of Medicine finds depression stems from miscommunication between brain cells 3Significant contribution of Greenland's peripheral glaciers to sea-level rise 2
Rabbit polyclonal to MAL ( Abpromise for all tested applications). entrezGeneID: 4118 SwissProtID: P21145...
Glutamate Receptor 5/1a...
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 50 ug...
Biology Products: